Cardiogen vs Nattokinase
A side-by-side research comparison of Cardiogen and Nattokinase across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cardiogen | Nattokinase |
|---|---|---|
| Full name | Cardiogen (Ala-Glu-Asp-Arg Cardiac Bioregulator) | Nattokinase (Subtilisin NAT) |
| Category | Cardiovascular | Cardiovascular |
| Status | Research compound (peptide bioregulator) | Dietary supplement |
| Mechanism | As a signal peptide (Ala-Glu-Asp-Arg), it is proposed to regulate gene expression in myocardial tissue, supporting cardiomyocyte function, myocardial protein synthesis, and normal cardiac tissue maintenance. | Directly degrades fibrin in blood clots via proteolytic activity. Also activates endogenous tissue plasminogen activator (tPA) and suppresses plasminogen activator inhibitor-1 (PAI-1), enhancing the body's own fibrinolytic system. |
| Molecular weight | ~460 Da | ~27,728 Da |
| Half-life | Short (peptide) | ~8-12 hours (fibrinolytic activity) |
| Bioavailability | Oral (encapsulated) or subcutaneous | Oral absorption confirmed; survives GI tract |
| Typical dose | ~1-2 capsules/day or short injectable courses | 2000-4000 FU (fibrinolytic units) |
| Frequency | Once daily | Daily on empty stomach |
| Route | Oral capsule or subcutaneous | Oral capsule |
Cardiogen reported benefits
- Cardiac/myocardial tissue support
- Cardiovascular resilience (proposed)
- Myocardial protein synthesis support
- Short course-based protocol
Nattokinase reported benefits
- Fibrin clot dissolution
- Blood pressure reduction
- Improved blood viscosity
- Reduced DVT risk
- Atherosclerosis prevention
- Natural anticoagulant alternative
Related comparisons
Research and educational reference only. Not medical advice.